Tools for Practice Outils pour la pratique


#219 Omega-3 Supplements for Dry Eye: Fishy evidence or a big catch?


CLINICAL QUESTION
QUESTION CLINIQUE
 Does oral omega-3 supplementation improve symptoms of dry eye disease?

BOTTOM LINE
RÉSULTAT FINAL
 The evidence for omega-3 is inconsistent. The best quality randomized control trial (RCT) found that omega-3 supplementation does not improve dry eye symptoms or function. Smaller RCTs suggest statistically significant benefits in symptom scores that are not always clinically relevant. At best, omega-3 will improve symptoms about 3.9 points more than placebo on an 18-point symptom score. 


CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

 Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session


EVIDENCE
DONNÉES PROBANTES
 Eleven RCTs of omega-3 [with both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] reporting patient-oriented outcomes: 
  • Best quality RCT, 535 patients, mean age 58, with moderate symptoms of dry eye disease. Outcomes at one year:1 
    • Omega-3 (2,000/1,000 mg EPA/DHA per day) versus placebo. 
    • No difference in symptom scores, patient function, objective measures, or adverse events. 
  • One RCT, 105 patients, mean age 57, with moderate Meibomian gland dysfunction. Outcomes at three months Omega-3 (1,680/560 mg EPA/DHA per day) versus placebo:2 
    • Statistical improvement on the 100-point Ocular Surface Disease Index: 
      • Attained score (lower better): 16 with omega-3 versus 22 with placebo.  
        • Difference likely not clinically relevant (minimal clinically important difference 7-10).3  
        • Ocular Surface Disease Index is the only assessment tool that includes symptoms, vision-related function and environmental triggers related to dry eye. 
    • Limitations: Industry funded.  
  • Four RCTs, 256-518 patients. At 1.5-6 months:4-7 
    • Omega-3 used ranged 325-720 mg for EPA and 175-480 mg DHA. 
    • Statistically significant improvement of 2.0-4.6 versus 0.2-0.7 points (placebo) on 18-point symptom scale. 
      • Maybe clinically relevant. 
    • Limitations: All written by the same lead author. Used a non-standard scale created by the authors that assesses symptoms but not patient function. 
  • Smaller RCTs report statistical but not clinically significant improvements with omega-3.8-12 
Context: 
  • Guidelines suggest artificial tear lubricants (~$11 per 30-day supply depending on usage), hot compresses, and environmental changes, such increasing humidity, for management of dry eyes.13,14 
  • There are no omega-3 dose recommendations for dry eyes provided in the guidelines. 13,14 
  • Cost of omega-3 supplementation is ~$60 per 90-day supply (based on a daily dose of 1,800/900 mg EPA/DHA). 

Latest Tools for Practice
Derniers outils pour la pratique
program image
Adrienne J Lindblad BSP ACPR PharmD

#377 How to slow the flow IV: Combined oral contraceptives

In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Read Lire 0.25 credits available Crédits disponibles
program image
Jennifer Potter MD CCFP

#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)

What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
Read Lire 0.25 credits available Crédits disponibles
program image
Betsy Thomas BScPharm

#375 Pharm for Fibro: Can antidepressants ease the pain?

Do antidepressants reduce pain in patients with fibromyalgia?
Read Lire 0.25 credits available Crédits disponibles
September 10, 2018

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session
Author(s)
Auteur(s)
  • Joey Ton PharmD
  • Christina Korownyk MD CCFP

1. Dry Eye Assessment and Management Study Research Group. N Engl J Med. 2018 May 3; 378(18):1681-90.

2. Epitropoulos AT, Donnenfeld ED, Shah ZA, et al. Cornea. 2016 Sep; 35(9):1185-91.

3. Miller KL, Walt JG, Mink DR, et al. Arch Ophthalmol. 2010 Jan; 128(1):94-101.

4. Bhargava R, Kumar P. Cornea. 2015 Apr; 34(4):413-20.

5. Bhargava R, Kumar P, Phogat H, et al. Cont Lens Anterior Eye. 2015 Jun; 38(3):206-10.

6. Bhargava R, Kumar P, Kumar M, et al. Int J Ophthalmol. 2013 Dec 18; 6(6):811-6.

7. Bhargava R, Kumar P, Arora Y. Eye Contact Lens. 2016 Jul; 42(4):231-6.

8. Deinema LA, Vingrys AJ, Wong CY, et al. Ophthalmology. 2017 Jan; 124(1):43-52.

9. Wojtowicz JC, Butovich I, Uchiyama E, et al. Cornea. 2011 Mar; 30(3):308-14.

10. Kawakita T, Kawabata F, Tsuji T, et al. Biomed Res. 2013; 34(5):215-20.

11. Olenik A, Jimenez-Alfaro I, Alejandre-Alba N, et al. Clin Interv Aging. 2013; 8:1133-8.

12. Malhotra C, Singh S, Chakma P, et al. Cornea. 2015 Jun; 34(6):637-43.

13. American Academy of Ophthalmology. Dry Eye Syndrome. Available from: https://www.aao.org/preferred-practice-pattern/dry-eye-syndrome-ppp--2013. Last Accessed: June 28, 2018.

14. Canadian Association of Optometrists. National Dry Eye Disease Guidelines for Canadian Optometrists. Available from: https://opto.ca/sites/default/files/resources/documents/cjo_dry_eye_supplement_2014.pdf. Last Accessed: June 28, 2018.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.